Medical aesthetic device maker Venus Concept's Q3 revenue misses

Venus Concept

13/11/2025 12:11

Overview

Venus Concept Q3 2025 revenue down 8% yr/yr, missing analyst expectations

Net loss widened to $22.5 mln in Q3, compared to $9.3 mln last year

Company completed debt-to-equity exchange, reducing debt by 24%

Outlook

Company is not providing financial guidance for fiscal year 2025

Company targets sequential growth in Q4 with Venus NOVA launch

Company faces challenges in closing Venus Hair Business sale

Result Drivers

EBD STABILIZATION - Venus Concept reports signs of stabilization in energy-based device revenues

HAIR BUSINESS DELAY - Decline in Venus Hair Business revenue due to delay in pending sale

VENUS NOVA LAUNCH - FDA clearance received for Venus NOVA, expected to drive future growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$13.8 mln
$14.48 mln (1 Analyst)
Q3 EPS
-$12.14
Q3 Net Income
-$22.50 mln
Q3 Adjusted EBITDA
-$7.80 mln
Q3 Gross Margin
64.00%
Q3 Operating Income
-$9.50 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Press Release: ID:nGNX3vylml

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)